TECX

Harvard Professor and $TECX Director Timothy Springer Buys $10.85M in Shares Amid Market Selloff—A Strong Vote of Confidence

04/11/2025 22:21

In the midst of a steep U.S. stock market decline, a board member of biotech company $TECX has been aggressively purchasing company shares, drawing significant investor attention. Timothy A. Springer, Director at Tectonic Therapeutic Inc, acquired a total of 641,923 shares worth approximately $10.85 million over just five days from April 7 to April 11. What makes these purchases particularly noteworthy is their timing during a period of extreme market volatility triggered by President Trump's tariff announcements. On April 7, when biotech stocks tumbled alongside crypto-related equities, $TECX was trading at $15.53, representing a 70% decline from its January peak. It was at this precise moment that Springer purchased 500,000 shares at an average price of $17.10. This transaction appears to have directly acquired shares sold by fellow board member Terrance McGuire, who disposed of exactly the same number of shares at the same price on the same day. Springer continued his buying spree with additional purchases of 24,789 shares on April 9, 53,950 shares on April 10, and 63,184 shares on April 11, investing an additional $2.3 million. His April 9 purchase notably coincided with the market's dramatic rally following President Trump's announcement of a 90-day pause on tariffs. This recent buying activity is consistent with Springer's previous investment pattern in the company. He previously acquired 50,000 shares on September 26, 2024, 300,000 shares on October 22, 2024, and a massive 789,294 shares worth $41 million on February 5, 2025. Tectonic Therapeutic is focused on developing innovative therapeutics targeting G-protein coupled receptors (GPCRs), with its lead candidate TX45 being developed for pulmonary hypertension. The company announced positive early-stage clinical data for TX45 on January 30, 2025, which sent shares soaring 104% to $52.50. However, the stock subsequently declined amid broader market weakness. With a market capitalization of approximately $314 million, $TECX exhibits the typical characteristics of a small-cap biotech firm whose valuation is heavily dependent on clinical trial outcomes. In its Q4 2024 earnings release in March 2025, the company reported a quarterly loss of $12.37 million, which represented an improvement from the same period the previous year. Timothy A. Springer, a Harvard Medical School professor and immunology authority, is also known as an influential biotech investor. He was an early investor in Moderna, reportedly generating billions in returns. Industry experts suggest that such significant insider buying from someone of Springer's caliber reflects strong confidence in the company's pipeline and future value. Wall Street analysts maintain an average 'buy' rating on $TECX with a median price target of $76, suggesting substantial upside from current levels. However, regulatory approval uncertainties and potential future capital requirements remain key risk factors, as is typical for early-stage biotech companies. Investors should monitor the progress of TX45's Phase 2 APEX clinical trial, with topline results expected in 2026. Patient enrollment updates and any interim data could serve as significant catalysts for the stock in the near term.

You can receive notifications when news is published.